JP7113409B2 - ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー - Google Patents

３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー Download PDF

Info

Publication number
JP7113409B2
JP7113409B2 JP2019523168A JP2019523168A JP7113409B2 JP 7113409 B2 JP7113409 B2 JP 7113409B2 JP 2019523168 A JP2019523168 A JP 2019523168A JP 2019523168 A JP2019523168 A JP 2019523168A JP 7113409 B2 JP7113409 B2 JP 7113409B2
Authority
JP
Japan
Prior art keywords
isomer
cyclic monophosphorothioate
guanosine
cyclic
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529523A5 (enExample
JP2019529523A (ja
Inventor
ハンス－ゴットフリート ゲニーサー
フランク シュヴェーデ
アンドレアス レンチュ
ペール エクストレーム
ヴァレリア マリゴ
フランソワ パケ－デュラン
Original Assignee
グレイバグ ヴィジョン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グレイバグ ヴィジョン インコーポレイテッド filed Critical グレイバグ ヴィジョン インコーポレイテッド
Publication of JP2019529523A publication Critical patent/JP2019529523A/ja
Publication of JP2019529523A5 publication Critical patent/JP2019529523A5/ja
Priority to JP2022107321A priority Critical patent/JP7672368B2/ja
Application granted granted Critical
Publication of JP7113409B2 publication Critical patent/JP7113409B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019523168A 2016-07-11 2017-06-29 ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー Active JP7113409B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022107321A JP7672368B2 (ja) 2016-07-11 2022-07-01 ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16178924 2016-07-11
EP16178924.3 2016-07-11
PCT/EP2017/066113 WO2018010965A1 (en) 2016-07-11 2017-06-29 New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022107321A Division JP7672368B2 (ja) 2016-07-11 2022-07-01 ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー

Publications (3)

Publication Number Publication Date
JP2019529523A JP2019529523A (ja) 2019-10-17
JP2019529523A5 JP2019529523A5 (enExample) 2020-08-06
JP7113409B2 true JP7113409B2 (ja) 2022-08-05

Family

ID=56411445

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523168A Active JP7113409B2 (ja) 2016-07-11 2017-06-29 ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー
JP2022107321A Active JP7672368B2 (ja) 2016-07-11 2022-07-01 ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022107321A Active JP7672368B2 (ja) 2016-07-11 2022-07-01 ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー

Country Status (5)

Country Link
US (2) US11407781B2 (enExample)
EP (1) EP3481842A1 (enExample)
JP (2) JP7113409B2 (enExample)
CA (1) CA3069586A1 (enExample)
WO (1) WO2018010965A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022140440A (ja) * 2016-07-11 2022-09-26 グレイバグ ヴィジョン インコーポレイテッド ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018041942A1 (en) * 2016-08-31 2018-03-08 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh New polymer linked multimers of guanosine-3', 5'-cyclic monophosphates
JP7161760B2 (ja) * 2017-02-03 2022-10-27 国立大学法人東北大学 複素環化合物
EP3679935A4 (en) * 2017-07-10 2021-04-21 Tohoku University REMOVAL AGENT WITH AUTOPHAGIC MECHANISM OF DAMAGED MITOCHONDRIA
CN117999269A (zh) 2021-09-06 2024-05-07 米雷卡医药有限公司 用于生产环状鸟苷-单磷酸酯类似物的改进方法
CA3267932A1 (en) 2022-10-05 2024-04-11 Mireca Medicines Gmbh MICROPARCEL AND IMPLANT FORMULATIONS FOR ANALOGUE CGMP THERAPY
EP4598580A1 (en) 2022-10-06 2025-08-13 Mireca Medicines GmbH Conjugates for neuroretinal drug delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007108A1 (en) 1988-02-01 1989-08-10 Bernd Jastorff Process for producing nucleoside-3',5'-cyclophosphates and nucleoside-3',5'-cyclothiophosphates
US5625056A (en) 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
WO1999025384A2 (en) * 1997-11-17 1999-05-27 University Of Miami Multimeric tethered ligands and their use in receptor-ligand interactions
MX2008006550A (es) 2005-11-23 2008-09-23 Ironwood Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos gastrointestinales.
EP2125027A2 (en) 2007-03-12 2009-12-02 Nektar Therapeutics De novo synthesis of conjugates
WO2009026697A1 (en) 2007-08-28 2009-03-05 University Of Manitoba A method of reducing a vasodilatory response using a guanylate cyclase pathway inhibitor or an h2o2 reducing agent
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
WO2012130829A1 (en) 2011-03-29 2012-10-04 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh New boranophosphate analogues of cyclic nucleotides
SG11201705913UA (en) 2015-01-23 2017-08-30 Dynavax Tech Corp Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof
US10322087B2 (en) 2015-03-16 2019-06-18 Mireca Medicines Gmbh Targeted liposomal delivery of cGMP analogues
WO2018009587A1 (en) 2016-07-05 2018-01-11 Orbis Wheels, Inc. Multi-wheel transmission
CA3069586A1 (en) 2016-07-11 2018-01-18 Mireca Medicines Gmbh New equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022140440A (ja) * 2016-07-11 2022-09-26 グレイバグ ヴィジョン インコーポレイテッド ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー
JP7672368B2 (ja) 2016-07-11 2025-05-07 ミレカ メディシンズ ゲゼルシャフト ミット ベシュレンクテル ハフツング ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー

Also Published As

Publication number Publication date
CA3069586A1 (en) 2018-01-18
EP3481842A1 (en) 2019-05-15
JP2022140440A (ja) 2022-09-26
JP7672368B2 (ja) 2025-05-07
US11407781B2 (en) 2022-08-09
US20220402964A1 (en) 2022-12-22
US12583882B2 (en) 2026-03-24
US20190292214A1 (en) 2019-09-26
WO2018010965A1 (en) 2018-01-18
JP2019529523A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
JP7672368B2 (ja) ３’，５’－環状グアノシン一リン酸の新規エクアトリアル修飾ポリマー連結マルチマー
US11001605B2 (en) Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
SA517380651B1 (ar) مثبطات ديميثيلاز-1 خاص بلايسين
KR20160043534A (ko) 선택적 ｇｒｐ９４ 저해제 및 이의 용도
US12384813B2 (en) Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates
JP2022533421A (ja) 核酸、薬物組成物及び複合体ならびに調製方法と使用
CN112516164B (zh) 一种抑制肿瘤转移的氨基富勒烯材料
US9221868B2 (en) Uridine di- or tri-phosphate derivatives and uses thereof
TW201328710A (zh) 使用組織特異性擬肽配位體之標的遞送
WO2025119390A1 (zh) P2x7受体拮抗剂
CA3159980A1 (en) Targeting mb2 of the myc oncogene and its interaction with trrap in cancer
CN113286600A (zh) 核酸复合物
JP7080813B2 (ja) 細胞透過性のシアニド結合抗体
WO2019136310A2 (en) Novel compounds for the treatment of neurodegenerative diseases
JP6215455B2 (ja) 化合物投与前駆体及び薬物担体製剤
US20250276036A1 (en) Composition for the inhibition of nrf2 and uses thereof in cancer therapy
CN102532192A (zh) 一种对乙酰氨基酚—磷酰氮芥抗肿瘤药物及其制备方法
WO2025140434A1 (zh) 一种肝靶向化合物及其在药物缀合物中的用途
TW202539738A (zh) 適體及聚乙基噁唑啉之共軛物
KR20250051117A (ko) 스테로이드 또는 비타민을 갖는 중합체
WO2015039592A1 (zh) 用于治疗癌症的化合物及其制备方法和用途
Xie et al. A paper to be submitted to the Journal of Molecular Biology
Su'etsugu et al. Reconstitution of in vitro inactivation and reactivation systems of DnaA protein for the control of chromosomal replication initiation in Escherichia coli
HK1250922B (zh) 肽寡核苷酸缀合物
JPS6396553A (ja) 充填剤

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220601

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220701

R150 Certificate of patent or registration of utility model

Ref document number: 7113409

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250